# PATENT COOPERATION TREATY

# TRANSLATION INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

(Chapter II of the Patent Cooperation Treaty)

(PCT Article 36 and Rule 70)

Applicant's c	r agent's file referen 308P	ce	FOR FURTHER ACT	ON	See Form PCT/IPEA/416		
International application No.			International filing date (a	lay/month/year)	Priority date (day/month/year)		
PCT/JP2004/014207			29.09.2004		29.09.2003		
International	Patent Classification	n (IPC) or nation	onal classification and IPC				
	C12N15/09 A61K45/00 A61P1/16 A61P11/06 A61P31/12 A61P31/14 A61P35/00 A61P37/04						
Applicant CHUGAI SEIYAKU KABUSHIKI KAISHA							
			ninary examination report, e applicant according to Ar		nternational Preliminary Examining Authority		
2. Th	is REPORT consists	of a total of	11	sheets, including	g this cover sheet.		
3. Th	is report is also acco	mpanied by A	NNEXES, comprising:				
a. (sent to the applicant and to the International Bur				ı) a total of	sheets, as follows:		
į	sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications authorized by this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions).						
	sheets which supersede earlier sheets, but which this Authority considers contain an amendment that goes beyond the disclosure in the international application as filed, as indicated in item 4 of Box No. I and the Supplemental Box.						
ь.	(sent to the	International	Bureau only) a total of (ind	icate type and number	r of electronic carrier(s))		
	1 disk				, containing a sequence listing and/or tables		
			readable form only, as incarative Instructions).		mental Box Relating to Sequence Listing (see		
4. Th	is report contains in	lications relati	ng to the following items:				
[2	Box No. I	Basis of the	report				
<u> </u>	Box No. II	Priority					
			hment of opinion with regard to novelty, inventive step and industrial applicability				
Box No. IV Lack of unity o			ty of invention	of invention			
Box No. V Reasoned statement under Article 35(2) with regard to novelty, inventi citations and explanations supporting such statement				lty, inventive step or industrial applicability;			
	Box No. VI	Certain doc	uments cited	nents cited			
	Box No. VII	Certain defe	ects in the international application				
	Box No. VIII	Certain obs	ervations on the internation	al application			
Date of sub	nission of the deman	ıd	Dat	te of completion of th	is report		
				•			
Name and mailing address of the IPEA/JP			Au	thorized officer			
Facsimile N	o		Tel	ephone No.			

Вох	No. I	Basis of the report	
1.		I to the language, this report is based on the internation nder this item.	al application in the language in which it was filed, unless otherwise
		report is based on translations from the original languag h is the language of a translation furnished for the purpo	e into the following language ses of:
		international search (Rule 12.3 and 23.1(b))	
	닏	publication of the international application (Rule 12.4)	
		international preliminary examination (Rule 55.2 and/o	
2.	With regard receiving O this report):	Office in response to an invitation under Article 14 are	eport is based on (replacement sheets which have been furnished to the referred to in this report as "originally filed" and are not annexed to
	the in	ternational application as originally filed/furnished	
	the de	escription:	
	pages	3	as originally filed/furnished
	pages	s*	received by this Authority on
	pages	*	received by this Authority on
	The cla	aims:	
	nos.		as originally filed/furnished
	nos.*		
	nos.*		
	nos.*		received by this Authority on
	the dr	rawings:	
	sheets	s	as originally filed/furnished
	sheets	s*	received by this Authority on
	sheets	s*	received by this Authority on
	a sequ	uence listing and/or any related table(s) - see Suppleme	ental Box Relating to Sequence Listing.
3.	The a	amendments have resulted in the cancellation of:	
-		the description, pages	
	$\Box$	the claims, nos.	
		,	
		<u> </u>	
		the sequence listing (specify):	
	_ ⊔	any table(s) related to sequence listing (specify):	
4.			ments annexed to this report and listed below had not been made, since ed, as indicated in the Supplemental Box (Rule 70.2(c)).
	닏	the description, pages	
		the claims, nos.	
		the drawings, sheets/figs	
		the sequence listing (specify):	
		any table(s) related to sequence listing (specify):	
Ŀ	If item 4 ap	oplies, some or all of those sheets may be marked "supe	rseded."

Box No. II	I Non-establishment of opinion with regard to novelty, inventive step and industrial applicability
	ons whether the claimed invention appears to be novel, to involve an inventive step (to be non obvious), or to be industrially have not been examined in respect of:
	the entire international application
$\boxtimes$	claims Nos11-13,15-18
becaus	e:
	the said international application, or the said claims Nos.  relate to the following subject matter which does not require an international preliminary examination (specify):
	relate to the following subject matter which does not require an international premininary examination (specify).
	the description, claims or drawings (indicate particular elements below) or said claims Nos. 11-13, 15-18
لسا	are so unclear that no meaningful opinion could be formed (specify):
	With regards to the ligands, the agonists and
	the antagonists that are set forth in claims 11 to 13
	and 15 to 18, it was impossible to find any ligand,
	agonist or antagonist that is fully supported by the
	description in the meaning of PCT Article 6 or
	disclosed in the description in the meaning of PCT
	Article 5.
	the claims, or said claims Nos are so inadequately supported
_	by the description that no meaningful opinion could be formed.
$\boxtimes$	no international search report has been established for said claims Nos. 11-13, 15-18
	the nucleotide and/or amino acid sequence listing does not comply with the standard provided for in Annex C of the Administrative Instructions in that:
	the written form has not been furnished
	does not comply with the standard
	the computer readable form has not been furnished
	does not comply with the standard
	the tables related to the nucleotide and/or amino acid sequence listing, if in computer readable form only, do not comply with the technical requirements provided for in Annex C-bis of the Administrative Instructions.
	See Supplemental Box for further details.

		2 32, 332 23 3, 42 23
Box I	No. IV	Lack of unity of invention
1.		In response to the invitation to restrict or pay additional fees the applicant has:
		restricted the claims.
		paid additional fees.
		paid additional fees under protest.
		neither restricted the claims nor paid additional fees.
2.	$\boxtimes$	This Authority found that the requirement of unity of invention is not complied with and chose, according to Rule 68.1, not to invite the applicant to restrict or pay additional fees.
3.	This	Authority considers that the requirement of unity of invention in accordance with Rules 13.1, 13.2 and 13.3 is:
		complied with.
	$\boxtimes$	not complied with for the following reasons:
		The proteins that comprise an amino acid
		sequence represented by either SEQ ID NO: 2 or SEQ ID
		NO: 4 set forth in claim 1 and the proteins that
		comprise the amino acid sequence represented by SEQ ID
		NO: 6 set forth in claim 1 do not have a novel
		chemical structure in common, and are only linked by
		the fact that said proteins are NK cell receptor
		proteins. However, NK cell receptor proteins were well
		known prior to the priority date of the present
		application, as disclosed in the document JP 2003-
		527105 A, and thus the feature of being a NK cell
		receptor protein cannot be said to be a special
		technical feature as defined in PCT Rule 13.2.
:		[Refer to the Supplemental Box]
4.	Con	sequently, this report has been established in respect of the following parts of the international application:
٦.		all parts.
	$\square$	the parts relating to claims Nos. 1-10, 14, 19, 20

International application No.
PCT/JP2004/014207

Box	No. V Reasoned statement citations and explain	nt under Ar anations sup	ticle 35(2) with regard to novelty, inventive step or industrial applicability; porting such statement	
1.	Statement			
	Novelty (N)	Claims	8-10, 14, 19, 20	YES
		Claims	1-7	_ NO
	Inventive step (IS)	Claims		YES
		Claims	1-10, 14, 19, 20	NO
	Industrial applicability (IA)	Claims	1-10, 14, 19, 20	YES
		Claims		NO

2. Citations and explanations (Rule 70.7)

Document 1: EP 1201681 A

The inventions set forth in claims 1 to 7 lack novelty in the light of document 1 cited in the international search report. Document 1 discloses various receptor proteins that are collectively referred to as 'FAIL' proteins, the DNAs that encode said proteins, vectors and host cells that include said DNAs, and antibodies for binding said proteins. Therein, the FAIL proteins that are represented by SEQ ID NO: 6 and 34 correspond to fragments of the proteins that comprise the amino acid sequence represented by SEQ ID NO: 4 set forth in the present application and fragments of the proteins that comprise the amino acid sequence represented by SEQ ID NO: 2 set forth in the present application; therefore, the DNAs that encode the proteins in question can be said to be capable of hybridizing with DNA that comprises the base sequence represented by SEQ ID NO: 1 set forth in the present application and DNA that comprises the base sequence represented by SEQ ID NO: 3 set forth in the present application under stringent conditions. As a result, document 1 can be said to disclose the DNAs that are set forth in claim 1 (d) and claim 2 as well as the

International application No.
PCT/JP2004/014207

Box No. V Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

proteins that are set forth in claim 3, and thus document 1 can also be considered to disclose the vectors, the host cells and the antibodies that are set forth in claims 4 to 7.

In addition, it is common practice for a person skilled in the art to search for the ligands, the agonists and the antagonists that are associated with a receptor protein; likewise, it is also common practice for a person skilled in the art to configure a probe for detecting the DNA that encodes a receptor protein by producing a strand of at least 15 nucleotides which is complimentary to said DNA. Such being the case, the inventions set forth in claims 8 to 10, 14, 19 and 20 could easily have been invented by a person skilled in the art in the light of the disclosures in document 1.

Box	No. VI Cei	rtain documents cited			
1.	Certain published	documents (Rule 70.10)			
		Application No. Patent No.	Publication date (day/month/year)	Filing date (day/month/year)	Priority date (valid claim) (day/month/year)
	WO 03,	/89624 A	30.10.2003	25.03.2003	25.03.2002
	[E, X	]			
2.	Non-written discl	losures (Rule 70.9)		D	- Constitute Hardening
2.		losures (Rule 70.9)	Date of non-written of	lisclosure referrin	e of written disclosure g to non-written disclosure (day/month/year)
2.			Date of non-written o	lisclosure referrin	
2.				lisclosure referrin	g to non-written disclosure
2.				lisclosure referrin	g to non-written disclosure
2.				lisclosure referrin	g to non-written disclosure
2.				lisclosure referrin	g to non-written disclosure
2.				lisclosure referrin	g to non-written disclosure
2.				lisclosure referrin	g to non-written disclosure
2.	Kind	of non-written disclosure		lisclosure referrin	g to non-written disclosure
2.	Kind			lisclosure referrin	g to non-written disclosure
2.	Kind	of non-written disclosure		lisclosure referrin	g to non-written disclosure
2.	Kind	of non-written disclosure	(day/month/yed	lisclosure referrin	g to non-written disclosure
2.	Kind	of non-written disclosure	(day/month/yed	lisclosure referrin	g to non-written disclosure
2.	Kind	of non-written disclosure	(day/month/yed	lisclosure referrin	g to non-written disclosure
2.	Kind	of non-written disclosure	(day/month/yed	lisclosure referrin	g to non-written disclosure
2.	Kind	of non-written disclosure	(day/month/yed	lisclosure referrin	g to non-written disclosure

International application No.
PCT/JP2004/014207

Box No. VIII Certain observations on the international application

The following observations on the clarity of the claims, description, and drawings or on the question whether the claims are fully supported by the description, are made:

The disclosure "functionally similar" in claim 1 does not clearly specify either the function that is supposed to be similar or the manner in which said function is similar, and thus the scope of the invention that is set forth in claim 1 is unclear.

Supplemental Box Relating to Sequence Listing					
Continuation of Box No. I, item 2:					
<ol> <li>With regard to any nucleotide and/or amino acid sequence disclosed in the international application and necessary to the claimed invention, this report was established on the basis of:</li> </ol>					
a. type of material  a sequence listing  table(s) related to the sequence listing  b. format of material  in written format  in computer readable form  c. time of filing/furnishing  contained in the international application as filed					
filed together with the international application in computer readable form					
furnished subsequently to this Authority for the purposes of search and/or examination					
received by this Authority as an amendment* on					
2. In addition, in the case that more than one version or copy of a sequence listing and/or table(s) relating thereto has been filed or furnished, the required statements that the information in the subsequent or additional copies is identical to that in the application as filed or does not go beyond the application as filed, as appropriate, were furnished.					
3. Additional comments:					
* If item 4 in Box No. I applies, the listing and/or table(s) related thereto, which form part of the basis of the report, may be marked "superseded."					

International application No.
PCT/JP2004/014207

Supplement	al B	OX
------------	------	----

In case the space in any of the preceding boxes is not sufficient. Continuation of:

The Cover Sheet.

International Patent Classification (IPC) or national classification and IPC: Int.Cl.<sup>7</sup>

A61P 37/06 A61P 37/08 C07K 14/705 C07K 16/28 C12N1/15C12N1/19 C12N 1/21 C12N 5/00 C12P 21/02 C12Q 1/02 GO1N 33/15 GO1N 33/50

International application No.
PCT/JP2004/014207

Supplemental Box

Box IV

Such being the case, there cannot be said to be a technical relationship involving one or more of the same or corresponding special technical features which links the inventions pertaining to proteins that comprise an amino acid sequence represented by either SEQ ID NO: 2 or SEQ ID NO: 4 set forth in claim 1 and the inventions pertaining to proteins that comprise the amino acid sequence represented by SEQ ID NO: 6 set forth in claim 1 among the inventions that are set forth in claims 1 to 20, and thus the inventions in question cannot be said to be linked so as to form a single general inventive concept.

Consequently, the present international application does not conform to the requirements of unity of invention.